
AJUNTAMENT D'ALCOI
Website

Generalitat Valenciana
Website

Ayuntamiento de Valencia
Website

Cicloplast
Website

Ayuntamiento de Onil
Website

Anarpla
Website

Ayuntamiento de Mislata
Website

nlWA, North London Waste Authority
Website

Ayuntamiento de Salinas
Website

Zicla
Website

Fondazione Ecosistemi
Website

PEFC
Website

ALQUIENVAS
Website

DIPUTACI� DE VAL�NCIA
Website

AYUNTAMIENTO DE REQUENA
Website

UNIVERSIDAD DE ZARAGOZA
Website

OBSERVATORIO CONTRATACIÓN PÚBLICA
Website

AYUNTAMIENTO DE PAIPORTA
Website

AYUNTAMIENTO DE CUENCA
Website

BERL� S.A.
Website

CM PLASTIK
Website

TRANSFORMADORES INDUSTRIALES ECOL�GICOS

INDUSTRIAS AGAPITO
Website

RUBI KANGURO
Website
If you want to support our LIFE project as a STAKEHOLDER, please contact with us: life-future-project@aimplas.es
In this section, you can access to the latest technical information related to the FUTURE project topic.
Design, synthesis and bioactivity study on 5-phenylfuran derivatives as potent reversal agents against P-glycoprotein-mediated multidrug resistance in MCF-7/ADR cell
P-glycoprotein (P-gp)-mediated multidrug resistance (MDR) is a phenomenon in which cells become resistant to structurally and mechanistically unrelated drugs resulting in low intracellular drug concentrations. It is one of the noteworthy problems in malignant tumor clinical therapeutics. So P-gp protein is one of the ideal targets to solve MDR. Based on the lead compound 5m obtained from our previous work, a series of furan derivatives featuring alkyl-substituted phenols and 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline were designed and synthesized as reversal agents against P-gp in this paper. Compound 16 containing isopropoxy possessed good potency against P-gp mediated MDR in MCF-7/ADR (IC50 (doxorubicin)?=?0.73??M, RF?=?69.6 with 5??M 16 treated). Western blot results and Rh123 accumulation assays showed that 16 effectively inhibited P-gp efflux function but not its expression. The preliminary structure?activity relationship and docking studies demonstrated that compound 16 would be a potential P-gp inhibitor. Most worthy of mention is that compound 16 has achieved satisfactory results in combination with a variety of anti-tumor drugs, such as doxorubicin, paclitaxel, and vincristine. This study forwards a hopeful P-gp inhibitor for withstanding malignant tumor cell with multidrug resistance setting the basis for further studies.

» Author: Ya-Sheng Li, Xi Yang, Dong-Sheng Zhao, Yue Cai, Zhi Huang, Rui Wu, Si-Jia Wang, Gui-Jun Liu, Jian Wang, Xiao-Ze Bao, Xin-Yi Ye, Bin Wei, Zi-Ning Cui, Hong Wang
» Publication Date: 15/04/2021
C/ Gustave Eiffel, 4
(València Parc Tecnològic) - 46980
PATERNA (Valencia) - SPAIN
(+34) 96 136 60 40
Project Management department - Sustainability and Industrial Recovery
life-future-project@aimplas.es
